Loading…
NCX4016: a novel antithrombotic agent
Despite great advantages in antithrombotic treatments, important limitations of the presently available drugs encourage the search of more effective agents. Within the cardiovascular system, nitric oxide exerts several activities which may have an antithrombotic potential. Nitroaspirin in vitro inhi...
Saved in:
| Published in: | Digestive and liver disease 2003-05, Vol.35, p.S20-S26 |
|---|---|
| Main Authors: | , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c361t-bc33d1cd0710160f7d7d5ea504c6a5843811fb63e53e00b045123ab5a9bc3d233 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c361t-bc33d1cd0710160f7d7d5ea504c6a5843811fb63e53e00b045123ab5a9bc3d233 |
| container_end_page | S26 |
| container_issue | |
| container_start_page | S20 |
| container_title | Digestive and liver disease |
| container_volume | 35 |
| creator | Gresele, P Momi, S Mezzasoma, A.M |
| description | Despite great advantages in antithrombotic treatments, important limitations of the presently available drugs encourage the search of more effective agents.
Within the cardiovascular system, nitric oxide exerts several activities which may have an antithrombotic potential.
Nitroaspirin in vitro inhibits platelet aggregation and adhesion under shear conditions and smooth muscle cell proliferation—all activities not exerted by aspirin.
In vivo nitroaspirin exerts antithrombotic properties and prevents restenosis in hypercholesterolemic mice while aspirin is inactive.
Nitroaspirin has shown a number of significant advantages over the presently available antiplatelet agents; however, only clinical studies will say whether nitroaspirin represents a step forward in antithrombotic treatment. |
| doi_str_mv | 10.1016/S1590-8658(03)00048-3 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_73464524</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1590865803000483</els_id><sourcerecordid>73464524</sourcerecordid><originalsourceid>FETCH-LOGICAL-c361t-bc33d1cd0710160f7d7d5ea504c6a5843811fb63e53e00b045123ab5a9bc3d233</originalsourceid><addsrcrecordid>eNqFkEtPwzAQhC0EoqXwE0C5gOAQWMePpFwQqnhJFRwAiZvl2BswSpNip5X49zhtEUdOO4dvd3aGkEMK5xSovHimYgxpIUVxCuwMAHiRsi0ypEUehZDZdtS_yIDshfAJkFEpYJcMaFZwyTkMyfHj5I3He5eJTpp2iXWim851H76dlW3nTKLfsen2yU6l64AHmzkir7c3L5P7dPp09zC5nqaGSdqlpWHMUmMh71-EKre5FagFcCO1KDgrKK1KyVAwBCiBC5oxXQo9jps2Y2xETtZ35779WmDo1MwFg3WtG2wXQeUsvi0yHkGxBo1vQ_BYqbl3M-2_FQXVm6tVP6oPr4CpVT-qNzjaGCzKGdq_rU0hEbhaAxhjLh16FYzDxqB1Hk2nbOv-sfgBzphxzQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>73464524</pqid></control><display><type>article</type><title>NCX4016: a novel antithrombotic agent</title><source>ScienceDirect Journals</source><creator>Gresele, P ; Momi, S ; Mezzasoma, A.M</creator><creatorcontrib>Gresele, P ; Momi, S ; Mezzasoma, A.M</creatorcontrib><description>Despite great advantages in antithrombotic treatments, important limitations of the presently available drugs encourage the search of more effective agents.
Within the cardiovascular system, nitric oxide exerts several activities which may have an antithrombotic potential.
Nitroaspirin in vitro inhibits platelet aggregation and adhesion under shear conditions and smooth muscle cell proliferation—all activities not exerted by aspirin.
In vivo nitroaspirin exerts antithrombotic properties and prevents restenosis in hypercholesterolemic mice while aspirin is inactive.
Nitroaspirin has shown a number of significant advantages over the presently available antiplatelet agents; however, only clinical studies will say whether nitroaspirin represents a step forward in antithrombotic treatment.</description><identifier>ISSN: 1590-8658</identifier><identifier>EISSN: 1878-3562</identifier><identifier>DOI: 10.1016/S1590-8658(03)00048-3</identifier><identifier>PMID: 12846440</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject>Animals ; Antithrombotic agents ; Aspirin ; Aspirin - analogs & derivatives ; Aspirin - pharmacology ; Blood Platelets - drug effects ; Disease Models, Animal ; Fibrinolytic Agents - pharmacology ; Humans ; In Vitro Techniques ; Mice ; Monocytes - drug effects ; Nitric oxide ; Nitric Oxide - pharmacology ; Nitroaspirin ; Platelet Aggregation Inhibitors - pharmacology ; Pulmonary Embolism - drug therapy ; Rabbits ; Rats</subject><ispartof>Digestive and liver disease, 2003-05, Vol.35, p.S20-S26</ispartof><rights>2003 Editrice Gastroenterologica Italiana S.r.l.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c361t-bc33d1cd0710160f7d7d5ea504c6a5843811fb63e53e00b045123ab5a9bc3d233</citedby><cites>FETCH-LOGICAL-c361t-bc33d1cd0710160f7d7d5ea504c6a5843811fb63e53e00b045123ab5a9bc3d233</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12846440$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gresele, P</creatorcontrib><creatorcontrib>Momi, S</creatorcontrib><creatorcontrib>Mezzasoma, A.M</creatorcontrib><title>NCX4016: a novel antithrombotic agent</title><title>Digestive and liver disease</title><addtitle>Dig Liver Dis</addtitle><description>Despite great advantages in antithrombotic treatments, important limitations of the presently available drugs encourage the search of more effective agents.
Within the cardiovascular system, nitric oxide exerts several activities which may have an antithrombotic potential.
Nitroaspirin in vitro inhibits platelet aggregation and adhesion under shear conditions and smooth muscle cell proliferation—all activities not exerted by aspirin.
In vivo nitroaspirin exerts antithrombotic properties and prevents restenosis in hypercholesterolemic mice while aspirin is inactive.
Nitroaspirin has shown a number of significant advantages over the presently available antiplatelet agents; however, only clinical studies will say whether nitroaspirin represents a step forward in antithrombotic treatment.</description><subject>Animals</subject><subject>Antithrombotic agents</subject><subject>Aspirin</subject><subject>Aspirin - analogs & derivatives</subject><subject>Aspirin - pharmacology</subject><subject>Blood Platelets - drug effects</subject><subject>Disease Models, Animal</subject><subject>Fibrinolytic Agents - pharmacology</subject><subject>Humans</subject><subject>In Vitro Techniques</subject><subject>Mice</subject><subject>Monocytes - drug effects</subject><subject>Nitric oxide</subject><subject>Nitric Oxide - pharmacology</subject><subject>Nitroaspirin</subject><subject>Platelet Aggregation Inhibitors - pharmacology</subject><subject>Pulmonary Embolism - drug therapy</subject><subject>Rabbits</subject><subject>Rats</subject><issn>1590-8658</issn><issn>1878-3562</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><recordid>eNqFkEtPwzAQhC0EoqXwE0C5gOAQWMePpFwQqnhJFRwAiZvl2BswSpNip5X49zhtEUdOO4dvd3aGkEMK5xSovHimYgxpIUVxCuwMAHiRsi0ypEUehZDZdtS_yIDshfAJkFEpYJcMaFZwyTkMyfHj5I3He5eJTpp2iXWim851H76dlW3nTKLfsen2yU6l64AHmzkir7c3L5P7dPp09zC5nqaGSdqlpWHMUmMh71-EKre5FagFcCO1KDgrKK1KyVAwBCiBC5oxXQo9jps2Y2xETtZ35779WmDo1MwFg3WtG2wXQeUsvi0yHkGxBo1vQ_BYqbl3M-2_FQXVm6tVP6oPr4CpVT-qNzjaGCzKGdq_rU0hEbhaAxhjLh16FYzDxqB1Hk2nbOv-sfgBzphxzQ</recordid><startdate>20030501</startdate><enddate>20030501</enddate><creator>Gresele, P</creator><creator>Momi, S</creator><creator>Mezzasoma, A.M</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20030501</creationdate><title>NCX4016: a novel antithrombotic agent</title><author>Gresele, P ; Momi, S ; Mezzasoma, A.M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c361t-bc33d1cd0710160f7d7d5ea504c6a5843811fb63e53e00b045123ab5a9bc3d233</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Animals</topic><topic>Antithrombotic agents</topic><topic>Aspirin</topic><topic>Aspirin - analogs & derivatives</topic><topic>Aspirin - pharmacology</topic><topic>Blood Platelets - drug effects</topic><topic>Disease Models, Animal</topic><topic>Fibrinolytic Agents - pharmacology</topic><topic>Humans</topic><topic>In Vitro Techniques</topic><topic>Mice</topic><topic>Monocytes - drug effects</topic><topic>Nitric oxide</topic><topic>Nitric Oxide - pharmacology</topic><topic>Nitroaspirin</topic><topic>Platelet Aggregation Inhibitors - pharmacology</topic><topic>Pulmonary Embolism - drug therapy</topic><topic>Rabbits</topic><topic>Rats</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gresele, P</creatorcontrib><creatorcontrib>Momi, S</creatorcontrib><creatorcontrib>Mezzasoma, A.M</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Digestive and liver disease</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gresele, P</au><au>Momi, S</au><au>Mezzasoma, A.M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>NCX4016: a novel antithrombotic agent</atitle><jtitle>Digestive and liver disease</jtitle><addtitle>Dig Liver Dis</addtitle><date>2003-05-01</date><risdate>2003</risdate><volume>35</volume><spage>S20</spage><epage>S26</epage><pages>S20-S26</pages><issn>1590-8658</issn><eissn>1878-3562</eissn><abstract>Despite great advantages in antithrombotic treatments, important limitations of the presently available drugs encourage the search of more effective agents.
Within the cardiovascular system, nitric oxide exerts several activities which may have an antithrombotic potential.
Nitroaspirin in vitro inhibits platelet aggregation and adhesion under shear conditions and smooth muscle cell proliferation—all activities not exerted by aspirin.
In vivo nitroaspirin exerts antithrombotic properties and prevents restenosis in hypercholesterolemic mice while aspirin is inactive.
Nitroaspirin has shown a number of significant advantages over the presently available antiplatelet agents; however, only clinical studies will say whether nitroaspirin represents a step forward in antithrombotic treatment.</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>12846440</pmid><doi>10.1016/S1590-8658(03)00048-3</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1590-8658 |
| ispartof | Digestive and liver disease, 2003-05, Vol.35, p.S20-S26 |
| issn | 1590-8658 1878-3562 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_73464524 |
| source | ScienceDirect Journals |
| subjects | Animals Antithrombotic agents Aspirin Aspirin - analogs & derivatives Aspirin - pharmacology Blood Platelets - drug effects Disease Models, Animal Fibrinolytic Agents - pharmacology Humans In Vitro Techniques Mice Monocytes - drug effects Nitric oxide Nitric Oxide - pharmacology Nitroaspirin Platelet Aggregation Inhibitors - pharmacology Pulmonary Embolism - drug therapy Rabbits Rats |
| title | NCX4016: a novel antithrombotic agent |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T02%3A07%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=NCX4016:%20a%20novel%20antithrombotic%20agent&rft.jtitle=Digestive%20and%20liver%20disease&rft.au=Gresele,%20P&rft.date=2003-05-01&rft.volume=35&rft.spage=S20&rft.epage=S26&rft.pages=S20-S26&rft.issn=1590-8658&rft.eissn=1878-3562&rft_id=info:doi/10.1016/S1590-8658(03)00048-3&rft_dat=%3Cproquest_cross%3E73464524%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c361t-bc33d1cd0710160f7d7d5ea504c6a5843811fb63e53e00b045123ab5a9bc3d233%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=73464524&rft_id=info:pmid/12846440&rfr_iscdi=true |